Surgery Partners, Inc. (NASDAQ: SGRY) stands as a pivotal player in the U.S. healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $1.79 billion, the company operates a vast network of surgical facilities and offers a comprehensive range of services across multiple specialties. This positions Surgery Partners as a significant entity within the healthcare landscape, providing both ambulatory and in-hospital surgical solutions.
Investors currently see Surgery Partners’ stock priced at $13.66, with a modest price change of 0.41 (0.03%). It’s noteworthy that the stock has traded between $11.49 and $22.94 over the past year, reflecting a degree of volatility but also potential for substantial gains. The average analyst target price is $18.82, suggesting a potential upside of 37.76% from its current price level. This optimism is further bolstered by the fact that the stock enjoys a robust buy rating consensus with nine buy recommendations against three holds and zero sell ratings.
Despite the positive outlook, the company’s valuation metrics present a mixed picture. The forward P/E ratio is high at 48.79, indicating that the market expects significant earnings growth in the future. However, other valuation metrics such as the Price/Book and Price/Sales ratios are not available, which might suggest some opacity in financial metrics for potential investors. The lack of a trailing P/E ratio and a PEG ratio further complicates the traditional valuation analysis.
In terms of performance metrics, Surgery Partners recorded revenue growth of 2.70% and has a modest Return on Equity (ROE) of 2.32%. While the EPS is currently negative at -0.69, the company has generated a substantial free cash flow of $183.6 million, which is a critical liquidity indicator and can be a positive sign for future growth and debt management. Notably, the absence of dividends may deter income-seeking investors, as the company reinvests its earnings back into the business to fuel growth and expansion.
Technically, Surgery Partners’ current price is below both its 50-day and 200-day moving averages of $14.80 and $14.63, respectively, which can often be interpreted as a bearish signal. The RSI (14) stands at a low 18.77, suggesting that the stock might be oversold and could be poised for a rebound. However, the MACD reading of -0.32 against a signal line of -0.30 indicates a bearish momentum in the short term, which investors should watch closely.
Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners has grown into a formidable presence in the U.S. healthcare system. The company’s focus on non-emergency surgical procedures across diverse specialties, including orthopedics, ophthalmology, and gastroenterology, positions it well to capture a broad market segment. Coupled with its ancillary services and multi-specialty physician practices, Surgery Partners continues to expand its footprint in the healthcare industry.
As investors consider their next move, the analyst ratings and potential upside make Surgery Partners an intriguing investment prospect. However, potential investors should weigh the company’s growth potential against the current valuation metrics and technical indicators to make informed decisions.
